Table 3 Demographic and clinical characteristics of the Derivation, Validation and Easton cohorts.

Warfarin dose—mg/week

0.36

  Median

28.0

28.0

27.5

  Interquartile range

20.0–40.1

21.0–41.3

17.5–37.9

   VKORC1 rs9923231

0.34

      G/G

1473 (33.2)

372 (33.5)

35 (33.0)

      A/G

1651 (37.2)

389 (35.1)

54 (50.9)

      A/A

1309 (29.5)

348 (31.4)

17 (16.0)

   CYP2C9

0.12

      *1/*1

3330 (75.1)

856 (77.2)

62 (58.5)

      *1/*2

587 (13.2)

150 (13.5)

21 (19.8)

      *1/*3

403 (9.1)

75 (6.8)

19 (17.9)

      *2/*2

47 (1.1)

11 (1.0)

1 (0.1)

      *2/*3

51 (1.2)

16 (1.4)

3 (2.8)

      *3/*3

15 (0.3)

1 (0.1)

0 (0)

Age—no. (%)

0.65

    <50

738 (16.6)

192 (17.3)

2 (1.9)

    50–80

3146 (71.0)

790 (71.2)

56 (52.8)

    >80

549 (12.4)

127 (11.5)

48 (45.3)

Height—m

0.35

  Median

167.6

167.6

170.2

  Interquartile range

160.0–175.4

160.0–176.5

162.6–175.3

  Median

75.9

76.0

0.76

80.5

  Interquartile range

63.0–90.7

63.0–91.0

69.9–94.3

Race—no. (%)

0.44

  White

2418 (54.5)

585 (52.8)

106 (100)

  Asian

1161 (26.2)

298 (26.9)

  Black

492 (11.1)

140 (12.6)

  Mixed or missing

362 (8.2)

86 (7.8)

Amiodarone

211 (4.8)

58 (5.2)

0.51

10 (9.4)